Age features of the influence of ATP-LONG and molsidomine on heart and vascular contractions
The high incidence of cardiovascular discases, the long course and severity of diseases in the elderly and old patients determine the need to use effective and safe drugs for their treatment. The relevance of this study is determined by the feasibility of using drugs of metabolic action, which have a beneficial effect on the metabolism and energy metabolism of cardiomyocytes, improve vascular tone and blood supply to the myocardium, increase its contractile function. The effect of a combination of ATP-long and molsidomine on vascular and myocardial contractility in young and old rats was studied in in vitro experiments. In experiments on isolated segments of the thoracic aorta, it was found that combination of ATP-long and molsidomine has a vasodilating effect, which did not differ significantly from the action of acetylcholine in animals of both ages. Combined use of ATP-long and molsidomine did not significantly affect the contractility of the isolated heart of young rats under different perfusion regimens. In old rats, the use of a combination of ATP-long and molsidomine had a positive effect on the contractile function of the myocardium under the influence of damaging factors: prevented a decrease in left ventricular pressure during hypoxia and accelerated its growth during reperfusion. The results of the studies indicate a positive effect of the combination of ATP-long and molsidomine on the contractility of blood vessels and myocardium in older animals.
Chebotarev, D. F. Geriatrics in the internal medicine clinic. (in Russian). Heals: Kyiv, 1977, p. 3024
Korkushko, O. V. Geriatrics in therapeutic practice (in Ukrainian). Heals: Kyiv, 1993, p. 840
Korkushko, O. V.; Yaroshenko, Yu. T. Reserve capacities of the main functions of the cardiovascular system during aging (literature review and the results of own research) (in Russian). Problems of aging and longevity 2012, 21, 2, pp 119-152
Frolkis, V. V. Circulation and aging. Ed. Chebotarev, D. F. (in Russian). Science: Leningrad, 1984, p. 216
Bezrukov, V. V.; Kuprush, L. P., Gorchakova, N. O.; Belenichev, I. F.; Nagorna, O. O. et al. Pharmacotherapy in a geriatric clinic (in Ukrainian). Jurfund: Dnipro, 2019, p. 165
Yena, L. M.; Kuprush, L. P.; Kuprush, E. V. Comorbidity and polypharmacy in elderly and senile patients (in Russian). Journal of the Practitioner 2001, 3, pp. 29-33
Chaurasia, K. N.; Sinyh, A. K.; Gambhir, I. S. Rational drug therapy in elderly. J. Indian Academy of Geriatios 2005, 1, 3, pp. 82-88.
Chekman, I. S.; Gorchakova, N. A.; Zagorodny, M. I. et al. Cardioprotectors of metabolic action: expediency of experimental and clinical study (in Ukrainian). Zaporozhye medical journal 2003, 2, pp. 251-252
Amosova, E. N. Metabolic therapy of myocardial damage caused by ischemia. A new approach to the treatment of coronary artery disease and heart failure (in Russian). Ukrainian Journal of Cardiology 2000, 4, pp. 86-92
Vizir, V. R.; Voloshina, I. N.; Voloshin, N. A. Metabolic cardioprotectors: pharmacological properties and clinical use (in Russian). Zaporizhzhya state university: Zaporizhzhia, 2006, p. 36
Lipkan, G. M., Mkhitaryan, L. S.; Kutnyak, V. N. ATP-long is a representative of a new class of cardiotropic drugs (in Russian). Journal of the Practitioner 1999, 4, pp. 56-59
Zhigunov, A. K. Cardioprotective drug ATP-long and its effect on metabolic processes in the myocardium (in Russian). Ukr. Med. Journal 2012, 3, 89, pp. 65-71
Vdovichenko, N.; Smulsky, V.; Oliynyk, S. Pharmacological properties of the drug "ATP-long" (in Ukrainian). Sports medicine 2004, 1-2, pp. 105-109
Amosova, E. N.; Bereza, N. V.; Potapkova, I. V. The effect of complex therapy with the inclusion of ATP-LONG on the diastolic function of the left ventricle in patients with ischemic heart disease at rest and during isometric exercise (in Russian). Medical business 2002, 3-4, pp. 48-50
Mkhitaryan, L. S.; Amosova, K. M.; Bereza, N. V. Influence of macroergic phosphate (ATP-LONG) on the course of free radical processes, structural and functional state of cell membranes on ionic homeostasis in patients with initial forms of coronary heart disease (in Ukrainian). Ukrainian Journal of Cardiology 2000, 5-6, pp. 21-25
Volintseva, V. A. To the mechanism of action of exogenous ATP on the cardiovascular system. Topical issues of metabolism (in Russian). Materials of the 3rd conference on the physiology of metabolism in humans and animals: Vilnius, 1987, pp. 64-65
Starling, R. C.; Hammer, D. F.; Altschuld, R. A. Human myocardial ATP content and in vivo contractile function. Mol. Ctll. Biochem. 1998, 180, 1-2, pp. 171-177.
Hoka, S.; Takeshita, A.; Alshima, K. et al. Velodilaton effects of adenosine triphosphate and sodium nitroprusside: comparisons during controlled hypotension. J. Fnesth. 1987, 1,2, pp. 143-147.
Cohen, M. V.; Downey, J. M. Adenosine: trigger and mediator of cardioprotection. Basic. Res. Cardiol. 2008, 103, 3, pp. 203-215. doi: 10.1007/s00395-007-0687-7
Mclntosh, V. J.; Lasley, R. D. Adenosine receptor-mediated cardioprotection: are all 4 subtype required or redundant? J. Cardiovasc. Pharmacol. Ther. 2012., 17, 1, pp. 21-33. doi: 10.1177/1074248410396877
Gennari, F. J. Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit. Care Clin. 2002, 18, 2, pp. 273–288. doi: 10.1016/s0749-0704(01)00009-4
Schulman, M.; Narins, R. G. Hypokalemia and cardiovascular disease. Am. J. Cardiol. 1990, 65, 10, pp. 4E–9E. doi: 10.1016/0002-9149(90)90244-u
Shechter, M.; Sharir, M.; Labrador, M. J. et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000, 102, 19, pp. 2353–2358. doi: 10.1161/01.cir.102.19.2353
Pokan, R.; Hoffmann, P.; vjn Duvillard, S. P.; Smecal, G.; Wonisch, M. et al. Oral magnesium therapy exercise heart rate exercise tolerance and myocardial function in coronary artery disease patients. Br. J. Sports Med. 2006, 40, 9, pp. 773-778. doi: 10.1136/bjsm.2006.027250
Liao, F.; Folsom, A. R.; Brancati, F. L. In low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart. J. 1998, 136, 3, pp. 480-490. doi: 10.1016/s0002-8703(98)70224-8
Korotaeva, K .N.; Korotaeva, Yu. V.; Popova O.V. et al. Influence of free l-histidine on contractility and adrenergic reactivity of human and animal cardiomyocytes (in Russian). Materials of the IX Russian Scientific Conference "Rehabilitation and Secondary Prevention in Cardiology": Moscow, 2011, p. 62
Amosova, K. M.; Konopleva, L. F.; Mkhitiryan, L. S. et al. Clinical efficacy of a new domestic drug with metabolic action ATP-long® and its effect on the physical condition of patients with initial forms of coronary heart disease (in Ukrainian). Medicines of Ukraine 1999, 4, pp. 57-58
Denisyuk, V. I.; Lipnitskiy, T. N.; Sizova, M. M. et al. Increasing the effectiveness of antiarrhythmic and antianginal drugs when combined with ATP-long in elderly and senile patients with coronary artery disease (in Russian). Materials of the 1st Ukrainian scientific-practical conference “Cardiac arrhythmias: age aspects“: Kyiv, 2000, pp. 55-58
Messin, R.; Dubois, C.; Famaey, J.-P. Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities. Adv. Ther. 2008, 25, 11, pp. 1200–1214. doi: 10.1007/s12325-008-0117-8
Barbato, E.; Herman, A.; Benit, E.; Janssens, L.; Lalmand, J. et al. Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients with Stable AnginaPectoris Undergoing Percutaneous Coronary Intervention: the MEDCOR Trial. J Cardiovas Transtational Res. 2014, 7, pp. 226-231. doi: 10.1007/s12265-013-9513-9
Wohrle, J.; Hoher, T.; Hoffmalster, A.; Kestler, H. A.; Grebe, O.C. et al. (2003) Effect of molsidomine on rheological parametars and the incidence of cardiovascular events. Dtsch. Med. Wochenschr. 2003, 128, 24, pp. 1333-1337. doi: 10.1055/s-2003-39973
Schachinger, V.; Zaiher, A. M. Nitric oxide in therapy of angina pectoris: nitrates or molsidomine? Internist (berl.) 1997, 38, 5, pp. 438-447. doi: 10.1007/s001080050055
Kmlec, M.; Ochmanski, W. Molsidomine importance in treatment of circulation disorders. Przegl. Lek. 1998, 55, 10, pp. 532-536.
Vertkin, A. L.; Topolyansky, A. V. Molsidomin - new perspectives (in Russian). Russian medical journal 2004, 12, 5, pp. 364-366
Hug, J.; Hasentuss, G.; Wollchlager, H.; Just, H. J.; Bonzel, T. Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration. Med. Klin. (Munich) 1994, 89, 2, pp. 34-37
Messin, R.; Fenyvesi, T.; Carreer-Bruhwyler, F.; Crommen, J.; Chiap, P. et al. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg jnce-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations. Eur J Clin Pharmacol. 2003, 59, pp. 227-232. doi: https://doi.org/10.1007/s00228-003-0597-z
Chistik, T. Nitric oxide donors in the treatment of cardiovascular pathology: nitrates or sydnoneimines? (in Russian). Medicine and pharmacy news 2014, 1-2, pp. 485-486
Vapaatalo, H. NO-donors in cardiology. Pol. J. Pharmacol. 1994, 46, 6, pp. 531-540
Sjolin, L.; Hellstrand, P.; Clementz, B. An apparatus for mechanical experiments on isolated smooth muscle. Acta Physiol. Scand. 1978, 102, pp. 32A – 33A
Fallen, E. L.; Elliot, W. C,; Gorlin, R. Apparatus for study of ventricular function and metabolism in isolated perfused rat heart. J. Appl. Physiol. 1967, 22, 4, pp. 836- 839.